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INTRODUCTION
Triple-negative breast cancer (TNBC) is a molecular sub-
type of breast cancer known for its poor prognosis due to ag-
gressive biologic behavior with a high rate of metastasis and 
short relapse-free survival unlike luminal or human epider-
mal growth factor receptor 2 type breast carcinomas; it has no 
therapeutic targets, making chemotherapy the only option for 
adjuvant treatment.
After the GEPARDUO trial reported the therapeutic benefit 
of using a combination treatment regimen that consisted of 
doxorubicin and cyclophosphamide sequentially adminis-
tered with docetaxel, this regimen has become a standard 
therapeutic strategy for neoadjuvant systemic therapy in pa-
tients with operable breast cancers [1]. Although the retro-
spective analyses of clinical trials have reported a greater sen-
sitivity to cytotoxic chemotherapy in TNBC compared to hor-
mone receptor positive breast cancer [2,3], the pathologic 
complete response (pCR) rate was still low (28%–47%) [4-6]. 
Therefore, the need for a marker that can predict the response 
to a particular cytotoxic regimen, especially before neoadju-
vant chemotherapy (NAC), is becoming even more necessary 
for the optimization of therapeutic efficacy and prevention of 
unnecessary complications caused by systemic therapy.
To date, various predictive models and parameters for che-
motherapeutic response have been reported, especially based 
on transcriptional gene signatures; however, implementing 
them into routine practice has been challenging owing to a 
lack of consistency and reproducibility caused by tumor het-
erogeneity, particularly in TNBC. Histomorphological pheno-
types reflect the final product of the central dogma from tran-
scription to posttranscriptional modification pathways and 
they can be used as consistent predictive markers. In our pre-
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Purpose: There is no standard targeted therapy for the treatment 
of triple-negative breast cancer (TNBC). Therefore, its manage-
ment heavily depends on adjuvant chemotherapy. Using core 
needle biopsy, this study evaluated the histological factors of 
TNBC predicting the response to chemotherapy. Methods: One 
hundred forty-three TNBC patients who received single-regimen 
neoadjuvant chemotherapy (NAC) with the combination of doxo-
rubicin, cyclophosphamide, and docetaxel were enrolled. The 
core needle biopsy specimens acquired before NAC were used 
to analyze the clinicopathologic variables and overall perfor-
mance of the predictive model for therapeutic response. Results: 
Independent predictors of pathologic complete response after 
NAC were found to be higher number of tumor infiltrating lym-
phocytes (p=0.007), absence of clear cytoplasm (p=0.008), low 
necrosis (p=0.018), and high histologic grade (p=0.039). In the 
receiver operating characteristics curve analysis, the area under 
curve for the combination of these four variables was 0.777. 
Conclusion: The present study demonstrated that a predictive 
model using the above four variables can predict therapeutic re-
sponse to single-regimen NAC with the combination of doxoru-
bicin, cyclophosphamide, and docetaxel in TNBC. Therefore, 
adding these morphologic variables to clinical and genomic sig-
natures might enhance the ability to predict the therapeutic re-
sponse to NAC in TNBC.
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vious studies, particular phenotypes based on histologic char-
acteristics were proven strong predictors of lymph node me-
tastasis in different types of carcinomas including breast [7], 
colorectum [8], and thyroid [9,10].
Presently, preoperative core needle biopsy (CNB) is the gold 
standard procedure in cancer diagnostics. In addition to its 
diagnostic role, recent data have suggested another role for 
CNB in the analysis of predictive biomarkers, particularly uti-
lizing histomorphological characteristics [11-13]. This study 
evaluated the capacity of the histological characteristics ob-
served in CNB specimens for predicting the response to com-
bination chemotherapy with doxorubicin, cyclophosphamide, 
and docetaxel in TNBC patients. To our knowledge, studies 
reporting the role of the phenotypic features of CNB speci-
mens in predicting response to chemotherapy have been lim-
ited in TNBC patients, and this is the first study to suggest a 
novel use for CNB beyond its standard diagnostic use in 
breast cancer.
METHODS
Patient selection and study design
The study cohort included 143 patients with operable TNBC 
who received preoperative NAC followed by surgical resec-
tion at Seoul National University Hospital between January 
2009 and December 2014. The study inclusion criteria were as 
follows: (1) patients who received four to six cycles of NAC 
using doxorubicin with cyclophosphamide followed by 
docetaxel combination therapy (doxorubicin, 50 mg/m2; cy-
clophosphamide, 600 mg/m2; docetaxel, 75 mg/m2); (2) CNB 
samples with at least four well-preserved cores; and (3) pa-
tients with available corresponding surgical specimens to de-
termine the histological response. The clinicopathological pa-
rameters were reviewed and collected via an electronic medi-
cal records system. Clinical T stage was determined using 
magnetic resonance imaging data obtained before chemo-
therapy. This study was approved by the Institutional Review 
Board of Seoul National University Hospital (IRB number: 
1311-102-537).
Evaluation of the histopathological parameters
All hematoxylin and eosin-stained slides for surgical and 
CNB specimens were retrospectively reviewed by two breast 
pathologists (Y.Y.J. and H.S.R.) who were blinded to the clini-
cal details, and chemotherapeutic response to therapy was as-
sessed based on CTNoeBC [14]. The pCR was defined as hav-
ing no evidence of residual invasive carcinoma in both the 
breast tissue and regional lymph nodes determined by the 
analyses of the whole sections from primary tumors resected 
after chemotherapy. Residual carcinoma in situ was not taken 
into consideration for response assessment in the primary site.
The histological variables that were evaluated to determine 
the significant predictors of chemotherapeutic response using 
the CNB specimens were the histological grade of the CNB 
specimens, the percentage of the area occupied by the tumor 
infiltrating lymphocytes (TILs), retraction artifact status, 
small-cell like feature status, level of tumor necrosis, and clear 
cytoplasm status. The histological grade of the CNB specimen 
was determined before the administration of the cytotoxic 
agent according to the Nottingham grading system [15]. The 
percentage of the area occupied by the TILs over the total in-
tratumoral stromal area was estimated [16]. This percentage 
was further divided into four categories as follows: none, no 
infiltration of lymphocytes; mild, < 30%; moderate, 30% to 
60%; and severe, > 60% for lymphocytic infiltration (Figure 1) 
[17]. Based on this categorization, the four subgroups were 
further dichotomized into low TIL (none or mild) and high 
TIL (moderate or severe) groups. Intratumoral stromal TIL 
was defined as lymphocytes in the stroma between tumor 
cells without direct contact with the malignant cells according 
to the international TILs working group [16]. Additionally, we 
defined “peritumoral TIL” as the lymphocytes surrounding 
the peripheral border of the tumors as shown in Figure 2A. 
The relative proportions of peritumoral TIL and stromal TIL 
were determined. Tumors were considered intratumoral stro-
mal TIL-dominant if the intratumoral stromal TILs outnum-
bered the peritumoral TILs, and peritumoral TIL-dominant if 
the peritumoral TILs outnumbered the intratumoral stromal 
TILs.
The retraction artifact was defined as the existence of clear 
spaces that separate the tumor cells from the adjacent stroma 
without endothelial linings. A tumor was defined as having a 
retraction artifact if it had more than 20% of the tumor cells 
occupying the retraction artifact (Supplementary Figure 1A, 
available online) [18].
The small cell-like feature was defined as small hyperchro-
matic nuclei and scanty cytoplasm with crush artifact in tu-
mor cells (Supplementary Figure 1B, available online) [19]. A 
tumor was considered to have a small cell-like feature when 
more than 10% of the entire tumor area was occupied by cells 
having the defined phenotype [7].
Tumor necrosis was defined based on the presence of tu-
mor cell nests with eosinophilic debris accompanied by kary-
orrhexis and pyknosis [20]. A tumor was considered to have 
necrosis when at least one area with recognizable geographic 
necrosis was identified. The degree of necrosis was micro-
scopically assessed and divided into four categories, none, fo-
cal, partly, and diffuse, which were further dichotomized into 
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the low (none or focal) and high (partly or diffuse) groups 
(Figure 2B) [13].
Tumors with clear cytoplasm appeared as sheets of polyhe-
dral cells with well-defined cell membranes and clear cyto-
Figure 1. Representative microphotographs of tumor infiltrating lymphocytes (TIL) according to TIL grade (H&E stain, ×200). (A) None; almost no lym-
phocytes are present. (B) Mild; only a few lymphocytes infiltrate the tumor stroma. (C) Moderate; moderate lymphocytic infiltration in the stroma. (D) 





Figure 2. Representative histopathologic parameters. (A) Peritumoral tumor infiltrating lymphocytes (TIL); the lymphocytes surrounding the peripheral 
tumor border. The border between the tumor nests and the inner stroma is demarcated by the black line, and lymphocytes in the stroma surrounded 
by the line are considered to be stromal TIL (H&E stain, ×200). (B) The left half of the core biopsy specimen is totally necrotized. Diffuse necrosis (H&E 
stain, ×100). (C) Tumor cells with clear cytoplasm (H&E stain, ×400).
A B C
264  Yoon Yang Jung, et al.
http://ejbc.kr http://dx.doi.org/10.4048/jbc.2016.19.3.261
plasms (Figure 2C). A tumor was defined to have a clear cyto-
plasm when ≥ 10% of the tumor cells in the entire core had 
clear cytoplasms. Ductal carcinoma in situ, fat invasion, and 
lymphocytes in normal mammary glands were considered 
present if they were found in more than one area of the given 
core. 
Statistical analysis
Correlations between the clinicopathologic parameters and 
response to NAC were evaluated by univariate logistic regres-
sion analysis, and a multivariate logistic regression analysis 
was performed to identify the independent predictive factors. 
Receiver operating characteristics curves were constructed us-
ing the independent predictive factors identified by multivari-
ate analysis, and the area under the curve (AUC) was estimat-
ed for all variables, to determine the optimal cutoff values for 
all possible combinations of the variables. A p-value < 0.05 
was considered statistically significant. All statistical analyses 
Table 1. Univariate analysis of pathologic complete response and clinicopathologic parameters
Variable pCR (n=66), No. (%) Non-pCR (n=77), No. (%) OR 95% CI p-value
Age (yr)* 46.26±9.81 43.83±10.03 1.025 0.991–1.060 0.148
cT stage 0.038
   1,2 48 (72.7) 43 (55.8) 1
   3 18 (27.3) 34 (44.2) 0.474 0.235–0.959
Histologic grade 0.002
   II 29 (37.7) 42 (63.6) 1
   III 48 (62.3) 24 (36.4) 2.897 1.466–5.724
Mitotic count (/10HPF)* 17.61±17.30 19.30±14.49 0.993 0.972–1.014 0.523
TIL (%)† 0.029
   None 16 (24.2) 28 (36.4) 1
   Mild 7 (10.6) 18 (23.4) 0.681 0.234–1.979
   Moderate 17 (25.8) 12 (15.6) 2.479 0.948–6.481
   Severe 26 (39.4) 19 (24.7) 2.395 1.021–5.618
TIL (dichotomized) 0.003
   Low 23 (34.8) 46 (59.7) 1
   High 43 (65.2) 31 (40.3) 2.774 1.404–5.481
TIL location
   Peritumoral 23 (34.8) 41 (53.2) 1 0.028
   Intratumoral 43 (65.2) 36 (46.8) 2.129 1.083–4.185
Necrosis 0.001
   Low 50 (75.8) 36 (46.8) 1
   High 16 (24.2) 41 (53.2) 0.281 0.137–0.577
Clear cytoplasm 0.009
   Absent 42 (63.6) 32 (41.6) 1
   Present 24 (36.4) 45 (58.4) 0.406 0.207–0.799
Retraction artifact 0.431
   Absent 44 (66.7) 56 (72.7) 1
   Present 22 (33.3) 21 (27.3) 1.333 0.651–2.730
Small cell-like feature 0.673
   Absent 45 (68.2) 55 (71.4) 1
   Present 21 (31.8) 22 (28.6) 1.167 0.570–2.387
DCIS component 0.710
   Absent 56 (84.8) 67 (87.0) 1
   Present 10 (15.2) 10 (13.0) 1.196 0.465–3.080
Fat invasion 0.130
   Absent 42 (63.6) 58 (75.3) 1
   Present 24 (36.4) 19 (24.7) 1.744 0.848–3.588
Lymphocytes in normal glands 0.604
   Absent 28 (42.4) 36 (46.8) 1
   Present 38 (57.6) 41 (53.2) 1.192 0.614–2.311
pCR=pathologic complete response; OR=odds ratio; CI=confidence interval; cT stage=clinical T stage; HPF=high-power field; TIL= tumor infiltrating lympho-
cytes; DCIS=ductal carcinoma in situ.
*Mean±SD; †None, 0%; mild, <30%; moderate, 30%–60%; and severe, >60%.
Neoadjuvant Chemotherapy and Triple-Negative Breast Cancer 265
http://dx.doi.org/10.4048/jbc.2016.19.3.261 http://ejbc.kr
were performed using the IBM SPSS version 21.0 (IBM Corp., 
Armonk, USA).
RESULTS
Basal characteristics of the TNBC cohort
In the cohort of patients with TNBC, the median age was 
46 (31–68) years. The histological grade of the pre-NAC speci-
mens was 2 in 71 patients (49.7%) and 3 in 72 patients 
(50.3%). Nine cases (6.3%) were clinical stage 1, 82 (57.3%) 
were clinical stage 2, and 52 (36.4%) were clinical stage 3 (Ta-
ble 1).
Correlations between the clinicopathologic parameters and 
response to NAC in TNBC
Out of 143 patients, 66 patients (46.2%) achieved pCR to 
NAC while 77 (53.8%) failed to show pCR. The results of the 
univariate analysis performed to determine the correlations 
between the clinicopathologic parameters and response to 
NAC are summarized in Table 1. The factors showing signifi-
cant associations with pCR to NAC included low clinical T 
stage (p= 0.038), high histologic grade (p= 0.002), high num-
ber of TILs (p= 0.003), low degree of necrosis (p= 0.001), ab-
sence of clear cytoplasm (p= 0.009), and dominance of intra-
tumoral TILs over peritumoral TILs (p= 0.028). Multivariate 
analysis identified high TIL (OR, 3.484; p= 0.007), absence of 
clear cytoplasm (OR, 0.305; p= 0.008), low degree of necrosis 
(OR, 0.359; p= 0.018), and high histological grade (OR, 2.458; 
p= 0.039) as independent predictors of pCR (Table 2).
Predictive model for pCR to NAC in TNBC
We designed a predictive model for response to NAC using 
different combinations of the clinicopathologic variables that 
had been identified as independent predictors by multivariate 
logistic regression analysis. These variables included the histo-
logical grade, percentage of TILs, degree of necrosis, and 
small-cell feature. The AUC for the combination of the four 
variables was 0.777 (Figure 3).
DISCUSSION
Breast cancer is a group of heterogeneous diseases with nu-
merous genetic alterations yet relatively uniform histological 
phenotypes. Therefore, identification of the histological char-
acteristics that can help predict the therapeutic response or 
the clinical prognosis in CNB specimens can prove valuable. 
In the present study, we reviewed the histological character-
istics routinely encountered in CNB specimens and investi-
gated their capacity to predict the therapeutic response to 
combination therapy with Adriamycin, cyclophosphamide, 
and docetaxel, which is the standard cytotoxic regimen most 
widely administered in TNBC. As a result, four distinctive 
pathologic variables of TNBC including the histological grade, 
and the statuses of TIL, necrosis, and clear cytoplasm in tu-
mor cells were identified as strong predictors of the response 
to NAC. 
Recent subgroup analyses of NAC clinical trials have reported 
a relationship between the histologic grade and therapeutic 
sensitivity to pCR in TNBC [21,22]. In the Spanish Breast 
Cancer Research Group (GEICAM)/2006-03 Core-Basal phase 
II clinical trial, even though none of the clinicopathologic vari-
ables or gene signatures evaluated were identified as signifi-
cant predictors of pCR [22], there was a strong correlation be-
tween high histological grade and cytotoxic effects of NAC, 
which is consistent with the results of the present study. In our 
opinion, the higher pCR rate in tumors with high histologic 
grades might be attributable to the increased mitotic index, 
which is consistent with previous results showing that in-
Table 2. Multivariate analysis of pathologic complete response and clin-
icopathologic parameters
Variable OR 95% CI p-value
cT stage 0.473 0.200–1.122 0.089
Histological grade 2.458 1.047–5.774 0.039
TIL 3.484 1.407–8.627 0.007
Necrosis 0.359 0.154–0.838 0.018
Clear cytoplasm 0.305 0.126–0.736 0.008
OR=odds ratio; CI=confidence interval; cT stage=clinical T stage; TIL=tumor 
infiltrating lymphocytes.
Figure 3. Receiver operating characteristics analysis for prediction of 
pathologic complete response to neoadjuvant chemotherapy. 
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creased mitotic activity had a positive predictive role in breast 
cancer patients who received NAC [23,24]. In addition to high 
histological grade, tumor necrosis is another histological fea-
ture known to be associated with poor breast cancer-specific 
overall survival, particularly in patients with TNBC [25]. Ne-
crosis, an indicator of tumor hypoxia or low oxygen saturation 
around the tumor that ultimately results in resistance to che-
motherapy [26], has also been suggested as a predictor of re-
sponse to NAC. In the NAC setting of the present study, tu-
mor necrosis was a negative predictor of the response to NAC, 
which is consistent with the results of previous studies [13,27].
Furthermore, we identified clear cytoplasm as an additional 
histological feature of tumor cells that can help predict the re-
sponse to NAC. Although there is no clear evidence for the 
predictive role of clear cytoplasm in invasive mammary carci-
noma, a predominant clear cytoplasm feature was strongly as-
sociated with response to chemotherapy in ovarian carcinoma 
(another prevalent malignancy in females) [28]. Itamochi et 
al. [28] suggested that carcinomas with clear cell features 
showed distinct clinicopathologic behaviors that require new 
therapeutic strategies using specific targeted agents instead of 
conventional cytotoxic agents. 
Lymphocytic infiltration in tumors is another histomor-
phological characteristic of TNBC that is under investigation 
to develop a novel therapeutic strategy for the treatment of 
patients with TNBC. In the present study, tumor infiltration 
of the lymphocytes was assessed in three steps. First, the per-
centage of TILs was evaluated based on the recommendations 
from the international TILs working group [16]. Patients were 
categorized into four groups as previously suggested by 
Schalper et al. [17], and subsequently re-categorized into two 
groups. As a result, a significant association between the per-
centage of TILs and positive response to combination therapy 
with adriamycin, cyclophosphamide, and docetaxel was iden-
tified. These cytotoxic agents were previously reported to en-
hance the chemotherapeutic response in breast cancer via 
various mechanisms including tumor cell sensitization to T-
cell mediated cytotoxicity [29,30]. Docetaxel reinforces anti-
gen-specific cytotoxic T lymphocyte-mediated tumor cell cy-
totoxicity, which was also observed in the MCF-7 cell line [29]. 
In a murine breast cancer model, doxorubicin enhanced the 
cytotoxic effect of cytotoxic T cells and natural killer cells by 
eliminating the myeloid-derived suppressor cells [30]. These 
immunomodulatory effects of the chemotherapeutic agents 
underlie the correlation between the amount of TILs and che-
mosensitivity. In addition to the effect of the presence of TILs, 
we evaluated the role of the location of TILs; pCR rate was 
significantly higher when the lymphocytic infiltration to the 
intratumoral stroma outnumbered that to the peritumoral 
stromal area. To our knowledge, there have been no studies 
evaluating the role of TILs in the tumor border for TNBC. 
Further studies are warranted to determine the function of 
TILs in different locations of infiltration.
In conclusion, we propose a novel predictive model of ther-
apeutic response to the standard NAC regimen in TNBC us-
ing CNB specimens, a routine diagnostic tool employed in 
daily practice. The combined predictive model using four his-
tological variables including the histologic grade, tumor ne-
crosis, TILs, and clear cell feature were identified as relatively 
good predictors of response to NAC. The results of the present 
study might be utilized in a predictive model for therapeutic 
response in patients with TNBC who receive standard NAC 
with adriamycin, cyclophosphamide, and docetaxel.
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